Jennifer Chien
Net worth: 2 M $ as of 2026-05-30
Net worth: 2 M $ as of 2026-05-30
Jennifer L.
Chien is Executive Vice President & Head-North America at Rhythm Pharmaceuticals, Inc. since 2020.
Formerly, Ms. Chien was Vice President & Head-Genetic Diseases at Genzyme Therapeutics Ltd. from 2017 to 2020 and Chief Commercial Officer at Krystal Biotech, Inc. in 2020.
Ms. Chien completed graduate education at Harvard University and undergraduate education at the Massachusetts Institute of Technology.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-26 | 19,233 ( 0.03% ) | 2 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2020-11-08 |
| Companies | Position | End |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Corporate Officer/Principal | 2020-10-15 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 2019-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Krystal Biotech, Inc.
Krystal Biotech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops gene therapies to patients living with debilitating diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions